BBA
Baker Bros. Advisors Portfolio holdings
AUM
$10.3B
This Quarter Return
+18.16%
1 Year Return
+63.34%
3 Year Return
+231.6%
5 Year Return
+293.68%
10 Year Return
+1,612.7%
AUM
$9.8B
AUM Growth
+$9.8B
(+25%)
Cap. Flow
+$744M
Cap. Flow
% of AUM
7.6%
Top 10 Holdings %
Top 10 Hldgs %
73.27%
Holding
122
New
14
Increased
15
Reduced
12
Closed
1
Top Buys
Top Sells
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
$64.5M |
| 2 |
Xoma
XOMA
|
$22.1M |
| 3 |
AMBI
AMBIT BIOSCIENCES CORP COM STK (DE)
AMBI
|
$16.8M |
| 4 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
$15.4M |
| 5 |
RPRX
Repros Therapeutics Inc.
RPRX
|
$7.76M |
Sector Composition
| 1 | Healthcare | 42.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Rigel Pharmaceuticals
RIGL
$699M
| $1.09M | 0.01% |
481,972
| – | – |
|
102
Arcturus Therapeutics
ARCT
$476M
| $1.08M | 0.01% |
+289,871
| New | +$1.08M |
|
103
Alaunos Therapeutics
TCRT
$4.81M
| $982K | 0.01% |
193,640
-50,979
| -21% | -$259K |
|
|
FPRX
104
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $535K | 0.01% |
19,823
| – | – |
|
105
uniQure
QURE
$933M
| $454K | ﹤0.01% |
30,672
| – | – |
|
|
CCXI
106
DELISTED
ChemoCentryx, Inc.
CCXI
| $342K | ﹤0.01% |
50,000
| – | – |
|
107
Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock
CYCCP
| $82K | ﹤0.01% |
13,253
| – | – |
|
|
AST
108
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
| $54K | ﹤0.01% |
+16,775
| New | +$54K |
|
|
BTX.WS
109
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
| $22K | ﹤0.01% |
+20,525
| New | +$22K |
|
|
AMBI
110
DELISTED
AMBIT BIOSCIENCES CORP COM STK (DE)
AMBI
| – | – |
-1,093,332
| Closed | -$16.8M |
|